R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 52.75
-0.95 (-1.77%)
Sep 1, 2026, 4:00 PM EDT
R&G PharmaStudies Revenue
R&G PharmaStudies had revenue of 249.87M CNY in the quarter ending June 30, 2026, with 20.81% growth. This brings the company's revenue in the last twelve months to 939.31M, up 26.14% year-over-year. In the year 2025, R&G PharmaStudies had annual revenue of 851.01M with 14.38% growth.
Revenue (ttm)
939.31M
Revenue Growth
+26.14%
P/S Ratio
5.39
Revenue / Employee
355.13K
Employees
2,645
Market Cap
5.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 851.01M | 107.00M | 14.38% |
| Dec 31, 2024 | 744.00M | 22.63M | 3.14% |
| Dec 31, 2023 | 721.37M | 83.85M | 13.15% |
| Jan 1, 2023 | 637.52M | 29.09M | 4.78% |
| Jan 1, 2022 | 608.43M | 123.98M | 25.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Hvsen Biotechnology | 1.72B |
| Xiangxue Pharmaceutical | 1.48B |
| Shenzhen Weiguang Biological Products | 1.20B |
| ChemPartner PharmaTech | 1.14B |
| Boji Medical Technology | 961.34M |
| Beijing Konruns Pharmaceutical | 917.05M |
| PharmaResources (Shanghai) | 700.02M |
| Hangzhou Biotest Biotech | 459.42M |